Veradigm Inc. · OTC:MDRX
Veradigm — Allscripts Healthcare Solutions — J.P. Morgan Virtual Healthcare Conference 2021
16 slides from Veradigm's conference presentation, Jan 12, 2021
Slide 1: Allscripts Healthcare Solutions J.P. Morgan Virtual Healthcare Conference January 2021
Allscripts Healthcare Solutions J.P. Morgan Virtual Healthcare Conference| January 2021 Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including the preliminary financial information included in this presentation, are based on the current beliefs and expectati
Slide 3: 2020 was our year of reset
2020 was our year of reset Reset our cost base Reset our portfolio Reset our balance sheet/capital structure Reset our client priorities
Slide 4: Reset priorities to help our clients cope with COVID-19
Reset priorities to help our clients cope with COVID-19 COVID research database and clinical workflow initiatives Veradigm® Coordinated outpatient care across the continuum COVID Dashboards across connected client ecosystems Rapid Telehealth implementations Screening and assessment, real-time dashbo
Slide 5: Reset cost base
Reset cost base See reconciliation of non-GAAP metrics in the appendix of this presentation and posted on the Allscripts investor relations website. Expecting ~730 bps of Adjusted EBITDA margin improvement since 1Q20
Slide 6: Reset our portfolio
Reset our portfolio Collectively <10% of Consolidated Revenue = ~$1.25B After-Tax Proceeds $1.35B sale price >13x trailing revenue ~21x trailing Adjusted EBITDA Closed on December 31 $365M sale price ~7.5x trailing revenue ~18.5x trailing Adjusted EBITDA Closed on October 15
Slide 7: Reset balance sheet / capital structure
Reset balance sheet / capital structure Net Debt of $0 at 12/31/20 Targeting a long-term leverage ratio of ~1.5x Adjusted EBITDA Repurchased $280M of stock in 2020 via open market and accelerated programs Expect to repurchase a significant amount in 2021
Slide 8: Looking ahead to 2021
Looking ahead to 2021
Slide 9: Focus on the consumer
Focus on the consumer Physician burnout Inadequate interoperability Unifying care communities Genomics going mainstream Transition to value-based payment COVID-19 pandemic Allscripts is well positioned to help solve some of the most pressing issues in healthcare
Slide 10: Connecting data sources across the community to improve population health
Connecting data sources across the community to improve the health of entire populations Our Vision Delivering Interoperability Scale – 3rd Largest HIT Company Open EHR Adjacent Growth Platform with Veradigm Breadth and Depth >$1.5B investment in R&D and ~150 patents since 2016
Slide 11: Veradigm's unique data assets, analytics and last mile connectivity are a competitive advantage
Veradigm’s unique data assets, analytics and last mile connectivity are a competitive advantage Veradigm’s unique data assets, analytics and last mile connectivity are a competitive advantage Proprietary Data Sources at Scale Cross-platform data sources at scale and includes analytics and insights f
Slide 12: Financial Flywheel rebuilt in 2020 expected to drive significant yield in 2021
Financial “Flywheel” rebuilt in 2020 expected to drive significant Yield in 2021 Continued Focus on Returning Capital and Investing for Growth in Existing Business More Normalized Free Cash Flow Conversion Significantly Improved Adjusted EBITDA Margins Highly Recurring Revenue with Modest Organic Gr
Slide 13: Key investment highlights
Key investment highlights We enable providers, payers and life science companies to optimize value at the point of care Robust, diversified and award-winning solutions portfolio Strong balance sheet with demonstrated capacity for capital returns High recurring revenue model Track record of successfu
Slide 14: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures
Slide 15: Non-GAAP Financial Measures
Non-GAAP Financial Measures This presentation includes references to non-GAAP revenue, Adjusted EBITDA, Adjusted EBIDTA margin and free cash flow, which are considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Each of these m
Slide 16: Non-GAAP Reconciliation
Non-GAAP Reconciliation
Allscripts Healthcare Solutions — J.P. Morgan Virtual Healthcare Conference 2021 on 6ix